Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis - Summary - MDSpire
Advertisement
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis
To evaluate whether patients treated with abrocitinib 200 or 100 mg can achieve higher proportions of minimal disease activity compared to those treated with dupilumab or placebo.
Approach:
Study Design: Post hoc analysis of patients with atopic dermatitis receiving abrocitinib in the JADE DARE and JADE COMPARE clinical trials.
Patient Stratification: Patients were stratified by baseline itch score and evaluated for achieving EASI-90 + PP-NRS0/1.
Key Findings:
Patients treated with abrocitinib achieved minimal disease activity in a dose-dependent manner.
Higher proportions of minimal disease activity were achieved with abrocitinib 200 or 100 mg compared to dupilumab and placebo at week 16.
Abrocitinib 200 mg showed results as early as week 2.
Patients unresponsive to dupilumab were able to achieve minimal disease activity with abrocitinib.
Interpretation:
Abrocitinib may provide minimal disease activity in patients with moderate-to-severe atopic dermatitis, regardless of baseline severity and prior dupilumab exposure.
Limitations:
The clinical validity of the combined endpoint of EASI-90 + PP-NRS0/1 has not yet been established.
Conclusion:
Abrocitinib demonstrates rapid and significant skin clearance and itch relief in patients with atopic dermatitis.
by Stephen Weidinger, Kristian Reich, Naiem Issa, H. Chih-ho Hong, Christopher G. Bunick, Pinaki Biswas, Gary Chan, Erman Güler, Melissa Watkins, Justine Alderfer
Two companion guidelines provide 41 evidence-based recommendations on treatment and prevention, along with 29 statements on comorbidity associations in patients under 18
